International Journal of Rheumatic Diseases

Aims & Scope

The International Journal of Rheumatic Diseases (formerly APLAR Journal of Rheumatology) is the official journal of the Asia Pacific League of Associations for Rheumatology.

The Journal accepts original articles on clinical or experimental research pertinent to the rheumatic diseases, work on connective tissue diseases and other immune and allergic disorders.

The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership.

Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers and the Editor.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	2
2024	2.40

Journal Rank

Year	Value
2024	9975

Journal Citation Indicator

Year	Value
2024	1542

SJR (SCImago Journal Rank)

Year	Value
2024	0.582

Quartile

Year	Value
2024	Q3

h-index

Year	Value
2024	62

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients

  Citation: 310

  Authors: Fereydoun, Bahar SADEGHI, Mandana, Farhad, Behrooz

• The epidemiology of osteoarthritis in Asia

  Citation: 246

  Authors: Marlene, Lisa, Lyn, Damian, Ester, Peter

• Effects of <i><scp>L</scp>actobacillus casei</i> supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double‐blind clinical trial

  Citation: 201

  Authors: Beitullah, Aziz, Elnaz, Sakineh Khatoun, Leila, Mohammad, Mohammad Reza, Javad

• Rituximab in intractable ocular lesions of Behcet’s disease; randomized single‐blind control study (pilot study)

  Citation: 190

  Authors: Fereydoun, Hormoz, Mozhgan, Bahar, Farhad, Abdolhadi, Cheyda, Massoomeh, Tahereh, Nasim

• Expression of Concern: Clinical and metabolic response to probiotic supplementation in patients with rheumatoid arthritis: a randomized, double‐blind, placebo‐controlled trial

  Citation: 186

  Authors: Batol, Hamid R., Shima, Modjtaba, Maryam, Parvaneh, Reyhaneh, Mohsen, Mohammad R., Zatollah

• Two new inflammatory markers associated with Disease Activity Score‐28 in patients with rheumatoid arthritis: neutrophil‐lymphocyte ratio and platelet‐lymphocyte ratio

  Citation: 169

  Authors: Ali UÄŸur, Adem, Ali, Yunus, Ramazan, Tayfun, Sinan, Sami

• Mesenchymal stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients

  Citation: 164

  Authors: Fereydoun, Bahar, Mandana, Behrooz

• Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity

  Citation: 146

  Authors: Samia Z., Tamer A., Sanaa A., Atef T., Iman M., Manal S.

• Chondrocyte apoptosis: a cause or consequence of osteoarthritis?

  Citation: 145

  Authors: Zaitunnatakhin, Mohammed

• Behcet’s disease in Iran: analysis of 6500 cases

  Citation: 145

  Authors: Fereydoun, Farhad, Cheyda, Hormoz, Abdolhadi, Massoomeh, Tahereh, Zahra, Roghieh, Farima, Bahar SADEGHI

---